vTv Therapeutics Wins FDA Orphan Drug Status for Sickle Cell Condition
vTv Therapeutics secured FDA Orphan Drug Designation for HPPD in sickle cell disease, bolstering partnership talks while its T1D drug cadisegliatin remains the top priority.
vTv Therapeutics has received Orphan Drug Designation from the U.S. Food and Drug Administration for its treatment targeting hereditary persistence of fetal hemoglobin, or HPPD, in patients with sickle cell disease, the company announced. The designation marks a regulatory milestone for the biotech firm as it navigates a dual-program development strategy.
The FDA grants Orphan Drug Designation to therapies aimed at rare diseases affecting fewer than 200,000 Americans, a status that carries significant commercial and regulatory incentives including seven years of market exclusivity, tax credits on clinical trial costs, and expedited regulatory review pathways. For vTv, the designation is expected to strengthen its position as it pursues licensing or co-development partnerships for the HPPD program.
Read more Hilco Real Estate Seeks Buyers for Detroit-Area Rail Properties →
Despite the sickle cell milestone, vTv Therapeutics indicated the company's primary focus remains on cadisegliatin, its lead late-stage candidate for type 1 diabetes. The HPPD program is being advanced in parallel, with the orphan designation intended to attract outside partners rather than divert internal resources from the diabetes pipeline.
The strategic separation of priorities reflects a common approach among smaller biotechs seeking to maximize asset value without overextending capital. By leveraging the FDA designation in partnership discussions, vTv aims to unlock external funding and expertise for the sickle cell program while preserving its core development bandwidth for cadisegliatin.
Continue reading at GlobeNewswire - Industry News on Financial Services.
